Ozempic, Wegovy Have Health Benefits Beyond Weight Loss, Studies Find
New studies reveal Ozempic and Wegovy, both versions of semaglutide, offer health benefits beyond weight loss, including reducing heart failure risks, COVID-19 deaths, and all-cause mortality. Presented at the European Society of Cardiology meeting and published in the Journal of the American College of Cardiology, the findings suggest these drugs could revolutionize cardiovascular care.
Highlighted Terms
Related News
New studies reveal Ozempic and Wegovy, both versions of semaglutide, offer health benefits beyond weight loss, including reducing heart failure risks, COVID-19 deaths, and all-cause mortality. Presented at the European Society of Cardiology meeting and published in the Journal of the American College of Cardiology, the findings suggest these drugs could revolutionize cardiovascular care.
Ozempic and Wegovy, containing semaglutide, reduced heart health risk by 20% in overweight/obese individuals over 3 years, with greater benefits for those with kidney disease, according to a clinical trial.